Moderna Q1 Revenue Triples on International COVID Vaccine Sales
Moderna reported $389 million in first-quarter revenue, more than tripling year-over-year and surpassing analyst expectations. International markets accounted for 80% of sales, driven by continued demand for its COVID-19 vaccine. The strong performance underscores the company's global reach and the sustained need for booster doses.
Key facts
- Moderna posted $389 million in Q1 revenue.
- Revenue more than tripled compared to the previous year.
- 80% of revenue came from international markets.
- Sales exceeded analyst expectations.
- Growth was driven by COVID-19 vaccine sales abroad.
Entities
Institutions
- Moderna
Sources
- Quartz —